Vical Incorporated (NASDAQ:VICL) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.02, Bloomberg Earnings reports. Vical had a negative net margin of 71.38% and a negative return on equity of 21.06%.

Shares of Vical (VICL) traded down 3.47% on Tuesday, hitting $2.50. The stock had a trading volume of 71,011 shares. The stock has a 50 day moving average of $2.59 and a 200 day moving average of $2.33. Vical has a 12-month low of $2.05 and a 12-month high of $4.50. The firm’s market cap is $27.74 million.

A number of brokerages have recently issued reports on VICL. Rodman & Renshaw reiterated a “buy” rating and issued a $9.00 price target on shares of Vical in a report on Monday, June 12th. HC Wainwright set a $9.00 price target on Vical and gave the company a “buy” rating in a report on Monday, June 12th.

ILLEGAL ACTIVITY NOTICE: “Vical Incorporated (VICL) Posts Earnings Results, Misses Estimates By $0.02 EPS” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at

An institutional investor recently raised its position in Vical stock. Renaissance Technologies LLC raised its position in shares of Vical Incorporated (NASDAQ:VICL) by 9.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 392,509 shares of the biotechnology company’s stock after buying an additional 35,500 shares during the period. Renaissance Technologies LLC owned 3.55% of Vical worth $903,000 at the end of the most recent reporting period. 23.65% of the stock is owned by hedge funds and other institutional investors.

Vical Company Profile

Earnings History for Vical (NASDAQ:VICL)

Receive News & Ratings for Vical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Incorporated and related companies with's FREE daily email newsletter.